Please login to the form below

Not currently logged in
Email:
Password:

EFPIA confirms first and second vice-presidents

Novo Nordisk CEO Lars Fruergaard Jørgensen appointed first vice-president and Servier president Olivier Laureau confirmed as second vice-president

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has confirmed Lars Fruergaard Jørgensen (pictured above, left) as its new first vice-president and Olivier Laureau (pictured above, right) as second vice-president.

Fruergaard Jørgensen currently serves as the president and chief executive officer of Novo Nordisk, while Laureau serves as president of French pharma company Servier.

Commenting on his appointment, Jørgensen said: “From an ageing population and the burden of chronic disease, to environmental sustainability and fiscal constraints, we are committed to tackling societal challenges in partnership.

“That includes working with governments to reduce access delays and improve the availability of medicines for patients across Europe.  I look forward to working with the EFPIA Board and the wider community to achieve the shared goal of building a future EU health and innovation union.”

Meanwhile, Laureau said: “Recent events have demonstrated the key role medical innovation plays in keeping our society safe and healthy.  Our ambition is for Europe to be a world leader in life science.

“Realising that goal means EFPIA and its membership working with the EU and Member States to build a world-class regulatory system, a strong and predictable IP framework and a next generation life sciences eco-system that delivers for patients across Europe and around the world.”

The EFPIA also confirmed Hubertus von Baumbach, chairman of the board of managing directors at Boehringer Ingelheim, as president for the next two years.

Article by
Lucy Parsons

24th June 2021

From: Regulatory

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...